Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!

× No keyword cloud information.

8 in total

1. Translational genomics: the challenge of developing cancer biomarkers.

Authors: James D Brooks
Journal: Genome Res Date: 2012-02 Impact factor: 9.043

Review 2. Prostate Cancer Epigenetics: From Basic Mechanisms to Clinical Implications.

Authors: Srinivasan Yegnasubramanian; Angelo M De Marzo; William G Nelson
Journal: Cold Spring Harb Perspect Med Date: 2019-04-01 Impact factor: 6.915

Review 3. Treatment options in hormone-refractory prostate cancer: current and future approaches.

Authors: K A Harris; D M Reese
Journal: Drugs Date: 2001 Impact factor: 9.546

Review 4. Second-line treatment of metastatic prostatic carcinoma.

Authors: D W Newling
Journal: Urol Res Date: 1997

5. Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases.

Authors: O Santos; C D McDermott; R G Daniels; K Appelt
Journal: Clin Exp Metastasis Date: 1997-09 Impact factor: 5.150

Review 6. Prostate cancer, Incidence, management and outcomes.

Authors: E J Small
Journal: Drugs Aging Date: 1998-07 Impact factor: 3.923

Review 7. Suramin's development: what did we learn?

Authors: Maninderjeet Kaur; Eddie Reed; Oliver Sartor; William Dahut; William D Figg
Journal: Invest New Drugs Date: 2002-05 Impact factor: 3.651

Review 8. Prostate cancer epigenetics and its clinical implications.

Authors: Srinivasan Yegnasubramanian
Journal: Asian J Androl Date: 2016 Jul-Aug Impact factor: 3.285

8 in total